News

Patients who underwent bilateral treatment experienced a higher rate of clinically relevant recovery, the authors reported.

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

SightScore is a saliva test that looks at millions of genetic variants in the patient’s genome to create a personalized polygenic risk score for glaucoma.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sharon Fekrat, MD, FACS, FASRS talked about multi-modal retinal and choroidal imaging to diagnose and identify neurodegenerative diseases using machine learning.

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

Children experienced sudden vision loss, visual field constriction, nyctalopia and dyschromatopsia following febrile illness

Shah discusses several studies from the IRIS registry and plans for a retina program at next year's event to address the growing interest in retina procedures and techniques.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

At the Envision Summit 2025 in San Juan, Puerto Rico, Angela Zhu, MD, offered advice on cataract surgery for all ages, focusing on pediatrics.

OCU410 is a novel multifunctional modifier gene therapy candidate that targets multiple pathways associated with GA.

Advancements in drug durability and patient care are closing treatment gaps.

Professor Anat Loewenstein, MD, speaks about her presentation from the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting

The partnership with the NHS eye patient servicer will help preregistration optometrists access training in community and hospital settings

AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sherrol Reynolds, OD, FAAO, participated in a discussion on patient-centered care and the newest treatment strategies in neovascular AMD and DME.

The company shared 5-year results for lenadogene nolparvovec (Lumevoq), administered unilaterally and bilaterally to patients with Leber Hereditary Optic Neuropathy

The submission deadline for both the 2025 Jenny Pomeroy Award for Excellence in Vision and Public Health and the sixth annual Rising Visionary Award is Monday, March 10, 2025, at noon ET.

At the Envision Summit 2025 in San Juan, Puerto Rico, Ashley Wallace Tucker, OD, FAAO, FSLS, gave insight into advancements in keratoconus management and the importance of early detection as well as tips and advice on fitting scleral contact lens

The role of compounded anesthetic formulations in streamlining efficiency and elevating patient care.

The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

Examining the performance of AI algorithms versus human graders in neovascular age-related macular degeneration

The 15th annual meeting, taking from March 24–28 in Snowmass, Colorado, will deliver high-impact discussions on macular disease, artificial intelligence in ophthalmology, and breakthrough therapies—plus opportunities for networking on and off the slopes.

“Our current understanding of the pathophysiological basis of MacTel has led to the development of novel therapeutic approaches that may be able to break ground in this disease state.”

Advancements in lens technology reflect the growing popularity of multifocal lenses

At the Envision Summit 2025 in San Juan, Puerto Rico, Lana Rifkin, MD, gave clinicians advice on how, and when it may be most appropriate to use the new G2211 code.